01.23.23
Syner-G BioPharma Group, a provider of pharmaceutical science and regulatory consulting services, has acquired RMC Pharmaceutical Solutions (RMC). RMC supports the outsourced CMC and Quality needs of biotech and pharma companies across multiple therapeutic areas. Financial terms were not disclosed.
The acquisition provides additional pharmaceutical science services, adding development experience in all biologic modalities including cell and gene therapy. The combined team offers a range of process and analytical development services, regulatory strategy, regulatory submission support, and quality management services. For RMC, the acquisition provides biotech and pharma clients access to a full range of integrated development and regulatory services.
The combination enhances their ability to deliver high caliber CMC services to pharma and biotech companies of all sizes on a global basis.
“I am very pleased to welcome the RMC team to Syner-G,” said Ron Kraus, chief executive officer, Syner-G BioPharma Group. “RMC’s Biologics experience and their ‘Responsive, Measured, and Creative’ approach to product development fits perfectly with Syner-G’s vision to be the trusted development partner to our clients, recognized globally for our strategic, innovative, and scientifically-driven approach.”
"Our clients have come to expect high levels of critical thinking, informed by the best science and engineering, applied reliably, nimbly, and phase appropriately to solve problems and advance their programs," said Scott Rudge, co-founder, chairman, and chief operating officer of RMC. "We know that’s exactly what they will continue to receive from Syner-G and I’m delighted to continue to play a key role in the combined business." Timothy Joy, co-founder, president, and chief executive officer of RMC added, “In addition to the obvious benefits the combined organization presents to RMC’s clients, I’m excited about the future opportunities that being part of a larger organization offers to the RMC team.”
The acquisition provides additional pharmaceutical science services, adding development experience in all biologic modalities including cell and gene therapy. The combined team offers a range of process and analytical development services, regulatory strategy, regulatory submission support, and quality management services. For RMC, the acquisition provides biotech and pharma clients access to a full range of integrated development and regulatory services.
The combination enhances their ability to deliver high caliber CMC services to pharma and biotech companies of all sizes on a global basis.
“I am very pleased to welcome the RMC team to Syner-G,” said Ron Kraus, chief executive officer, Syner-G BioPharma Group. “RMC’s Biologics experience and their ‘Responsive, Measured, and Creative’ approach to product development fits perfectly with Syner-G’s vision to be the trusted development partner to our clients, recognized globally for our strategic, innovative, and scientifically-driven approach.”
"Our clients have come to expect high levels of critical thinking, informed by the best science and engineering, applied reliably, nimbly, and phase appropriately to solve problems and advance their programs," said Scott Rudge, co-founder, chairman, and chief operating officer of RMC. "We know that’s exactly what they will continue to receive from Syner-G and I’m delighted to continue to play a key role in the combined business." Timothy Joy, co-founder, president, and chief executive officer of RMC added, “In addition to the obvious benefits the combined organization presents to RMC’s clients, I’m excited about the future opportunities that being part of a larger organization offers to the RMC team.”
